Compare AIR & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIR | TERN |
|---|---|---|
| Founded | 1951 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.8B |
| IPO Year | 1994 | 2021 |
| Metric | AIR | TERN |
|---|---|---|
| Price | $113.14 | $52.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $131.20 | $45.22 |
| AVG Volume (30 Days) | 312.7K | ★ 3.3M |
| Earning Date | 03-24-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8.04 |
| EPS | ★ 3.59 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $10.93 | N/A |
| P/E Ratio | $31.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $60.74 | $3.06 |
| 52 Week High | $127.21 | $53.19 |
| Indicator | AIR | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 74.51 |
| Support Level | $111.65 | $52.42 |
| Resistance Level | $121.05 | $53.19 |
| Average True Range (ATR) | 3.95 | 0.07 |
| MACD | 0.71 | -0.31 |
| Stochastic Oscillator | 65.95 | 97.30 |
AAR Corp is engaged in providing products and services to aviation, government and defense market. It operates in segments namely: The parts supply segment majorly consists of sales and leasing of USM and aftermarket distribution of new, OEM-supplied replacement parts; Repair & Engineering segment provides airframe maintenance, component repair, and landing gear overhaul services; Integrated Solutions segment consists of its fleet management and operations of customer-owned aircraft, customized performance-based supply chain logistics programs in support of the U.S. Department of Defense, flight hour component inventory; and The Expeditionary Services segment consists of products and services supporting the movement of equipment and personnel by the U.S. and foreign governments and NGOs.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.